BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update
by Renee Jackson · The Cerbat GemBriaCell Therapeutics Corp. (NASDAQ:BCTXW – Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 4,166 shares, a decline of 21.8% from the December 31st total of 5,328 shares. Based on an average trading volume of 173,275 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 173,275 shares, the short-interest ratio is presently 0.0 days.
BriaCell Therapeutics Price Performance
NASDAQ BCTXW traded down $0.00 on Friday, reaching $0.01. The company’s stock had a trading volume of 66,043 shares, compared to its average volume of 116,967. BriaCell Therapeutics has a twelve month low of $0.00 and a twelve month high of $0.25. The firm’s 50 day moving average is $0.04 and its two-hundred day moving average is $0.04.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic treatments for breast cancer and other solid tumors. The company’s research strategy centers on harnessing the body’s immune system to recognize and attack cancer cells, with an emphasis on off-the-shelf allogeneic platforms that can be readily administered without the need for patient-specific manufacturing.
The company’s lead candidate, Bria-IMT, is derived from a human breast tumor cell line engineered to express immune-stimulatory molecules designed to trigger both innate and adaptive anti-tumor responses.